A Leukemic Target with a Thousand Faces: The Mitochondria

In the era of personalized medicine greatly improved by molecular diagnosis and tailor-made therapies, the survival rate of acute myeloid leukemia (AML) at 5 years remains unfortunately low. Indeed, the high heterogeneity of AML clones with distinct metabolic and molecular profiles allows them to su...

Descripción completa

Detalles Bibliográficos
Autores principales: Maffeo, Beatrice, Panuzzo, Cristina, Moraca, Amedeo, Cilloni, Daniela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10487524/
https://www.ncbi.nlm.nih.gov/pubmed/37685874
http://dx.doi.org/10.3390/ijms241713069

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10487524/
https://www.ncbi.nlm.nih.gov/pubmed/37685874
http://dx.doi.org/10.3390/ijms241713069

Ejemplares similares